Hemogenyx Pharmaceuticals PLC – FLT3 Assay Ready for Phase I Trials at MD Anderson Page 1

LONDON, UNITED KINGDOM / ACCESSWIRE / September 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO)a clinical-stage biopharmaceutical group focused on the development of treatments for cancer and viral diseases, is pleased to announce the successful completion of the development of a clinical assay (“Assay”) designed to assess the expression of FLT3 protein in acute myeloid leukemia (“AML”) cells.

Assessing FLT3 protein expression in AML cells is critical to accurately identifying and recruiting patients for the upcoming Phase I clinical trials of the Company’s HEMO-CAR-T product candidate. The trials are expected to begin shortly at MD Anderson Cancer Center (“MD Anderson”), one of the world’s most respected centers dedicated exclusively to cancer patient care, research, education and prevention. The Phase I clinical trials are expected to be expanded to include the University of Pennsylvania Medical Center thereafter.